Abstract
Introduction
Studies have reported an association between lipoprotein lipase (LPL) gene and myocardial infarction in some populations. Therefore, the present study aimed to investigate the association of the HindIII polymorphism of the (LPL) gene with myocardial infarction and to explore its potential role in susceptibility in a South Indian population.
Subjects and methods
We included a total of 412 subjects (202 myocardial infarction patients and 210 age- and sex-matched controls). Demographic and clinical characteristics were collected. Lipid profiles were estimated. DNA was isolated and the LPL gene HindIII polymorphism was determined by polymerase chain reaction.
Results
Comparison of the lipid profiles between patients and controls showed that patients had statistically high significant values (p = 0.0001). The H+ H+ genotype of the LPL gene is associated with myocardial infarction. H+ H+ vs. H− H− was χ2 = 19.4, OR 3.1, CI 95% 1.8–5.2, p < 0.0001.
Conclusion
Our study strongly suggests that the LPL gene HindIII Hþ Hþ genotype is an independent risk factor for first MI.
Keywords: Myocardial infarction, HindIII polymorphism, Lipoprotein lipase, Coronary artery disease, South Indian population
1. Introduction
Myocardial Infarction (MI), also known as heart attack, is the irreversible necrosis of heart muscle secondary to prolonged ischemia. This usually results from an imbalance in oxygen supply and demand, which is most often caused by plaque rupture with thrombus formation in a coronary vessel, resulting in an acute reduction of blood supply to a portion of the myocardium. The classical symptoms of MI are shortness of breath, chest pain anxiety typically radiating to the left arm or left side of the neck, palpitations and vomiting. The important risk factors are previous history of vascular disease such as atherosclerosis, angina-heart attack or stroke and age – especially in men over 40 and women over 50 years.1
Lipoprotein lipase (LPL) plays a important role in lipid metabolism by hydrolyzing triglycerides in circulating lipoproteins, which constitutes the rate-limiting step in removal of triglyceride-rich lipoproteins, such as chylomicrons (CM) and very low-density lipoproteins (VLDL) from the circulation.2 Lipoprotein lipase is multifunctional enzyme, recently shown to serve as a ligand for low-density lipoprotein (LDL) receptor-related protein and to influence the hepatic secretion and uptake of VLDL and LDL cholesterol.3
The LPL gene, located in region 8p22, is composed of 10 exons, 9 introns and contains some restriction fragment length polymorphisms (RFLPs).4–6 Modifications in gene structure may affect LPL activity, resulting in lipid metabolism changes, such as slow hydrolysis of CM and VLDL, increased half life of LDL and CM, lower production of high density lipoproteins (HDL)7,8 and increased LPL activity.9 The HindIII (rs320) polymorphism is one of the most common LPL gene polymorphisms. It is an intronic base transition of thymine (T) to guanine (G) at position +495, which abolishes the restriction site for the enzyme HindIII. Several studies have shown that the common allele (H+) is significantly associated with high triglycerides (TG) levels and low HDL levels compared to the rare allele (H−).10–16 The LPL H+ H+ genotype presented elevated TG levels.17 Another study demonstrated that this genotype has a higher risk of myocardial infarction (MI) in patients over 90 years old, while H− allele carriers are protected against MI.18
Hence, the present study was aimed at assessing the association of the HindIII polymorphism of the LPL gene in MI patients of a South Indian population. In addition to this, classical risk factors and lipid profiles have been studied in all the subjects.
2. Methods
The study was carried out on 202 MI patients (male:female = 181:21) admitted to Osmania General Hospital, ICCU, Cardiology Division, Hyderabad, Andhra Pradesh, India. The patients were 54–68 years of age. The inclusion criteria for the current study was the patients with acute myocardial infarction who underwent coronary angiography, where as the patients with past history of coronary artery and vascular diseases, pulmonary, renal, hepatic disease were excluded from our study. For the present study, the selection of MI patient study group were free of diabetes. The reason is that Diabetes is a major risk factor for MI and it is well proven that LPL gene HindIII gene polymorphism is associated with lipid levels in diabetic patients. The present study was aimed to find out the association between LPL HindIII polymorphism and abnormal lipid levels in MI patients. On the basis of typical ECG changes, elevated cardiac markers and clinical history, the diagnosis was confirmed as MI by the cardiologists. The study was approved by the Ethical Committee and written informed consent was obtained from all the subjects. Blood samples were collected from patients after 13–15 h of fasting. Simultaneously, blood samples were collected from 210 healthy, age- and sex-matched (male: female = 184:26) controls (blood donors from the same hospital) aged between 56 and 67 years and all controls were non-hypertensive.
Information has been collected using a questionnaire on age, sex, height, weight (for calculating body mass index), cigarette smoking, exercise schedule, alcohol consumption and hypertension. Exercise criteria were defined by an individual doing 1 h daily in the form of brisk walking or gym activity. Hypertension was defined according to JNC-VII guidelines. Accordingly, hypertension was defined as a systolic blood pressure >140 mmHg and/or a diastolic blood pressure >90 mmHg, based on the average of two blood pressure measurements, or a patient's self reported history of hypertension. Smokers were defined as those reporting daily smoking. Ex-smokers and occasional smokers were classified as non-smokers. Since patients were found to drink alcohol in different forms and many were reluctant to admit the exact amount consumed, we defined alcohol usage as consumption of at least three alcoholic drinks in a week.
To do the genotyping of LPL HindIII Polymorphism, 5 ml venous blood was collected in a plain test tube and serum was separated. In the region of intron 8, the LPL gene containing HindIII polymorphism was amplified using the following primers: forward primer 5′-GATGTCTACCTGGATAATCAAAG-3′and the reverse primer was 5′-CTTCAGCTAGACATTGCTAGTGT- 3′. PCR reaction was carried out in a 50-uL reaction volume containing 100 ng of genomic DNA, 0.4 mmol/L of each primer, 0.2 mmol/L dNTPs (Invitrogen, USA), 2 mmol/L MgCl2 in 10% PCR buffer and 1 U of DNA polymerase. PCR involved an initial 5-min denaturation at 96 °C, initial denaturing at 94 °C for 1 min, annealing at 57 °C for 1 min and extension at 72 °C for 1 min, with a final extension at 72 °C for 7 min, total 35 cycles were kept. The PCR amplified 355-bp product was digested with 2.5 U of HindIII (MBI Ferments) at 37 °C for 4 h, and the fragments were separated on an ethidium bromide stained 2% agarose gel; the replacement of a thymine (T) with a guanine (G) base at position +495 abolished the HindIII cleavage by converting the recognition sequence for HindIII (AAGCTT) into AAGCGT. The presence of a 225-bp band and a 140-bp band represents the homozygous mutant H+ H+ genotype; 365-bp, 225-bp and 140-bp bands represent the heterozygous H+ H− genotype; and 365-bp bands represent the homozygous H− H− genotype. Total cholesterol (TCL), triglycerides (TGL), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) were estimated using a semi-automatic analyzer (ERBA, CHEM-7, and Transasia Biomedicals, India) using commercial kits (ERBA).
2.1. Statistics
Analysis of variance (ANOVA) test was performed for lipid profiles among controls and MI patients using SPSS software, 15.0 Windows version. For all cases, p < 0.05 was considered significant. Hardy–Weinberg law of equilibrium was tested for the LPL gene polymorphism in controls and MI patients, the genotype frequencies were in agreement with the law. The association between genotypes of MI patients and controls was examined by using the odds ratio (OR) with 95% confidence interval (CI) and chi-square analysis. Allelic frequencies for the HindIII polymorphic site were estimated by gene counting. Multivariate logistic regression analysis was done for adjusting the confounding factors with LPL genotypes.
3. Results
The demographic and clinical characteristics of the 210 controls and 202 MI patients are represented in Table 1. The mean age of the controls and patients were 61.3 ± 4.6 and 63.2 ± 3.96 years respectively. The sex ratios were comparable in both groups. The Body Mass Index was higher in MI subjects, as compared to controls. Smokers and alcoholics were predominant among patients. Only 32.3% were involved in exercise among MI subjects against 55.7% among controls. Hypertensive individuals were excluded among controls, where as 29.5% among MI patients.
Table 1.
Characteristics | Controls n = 210(%) | MI patients n = 202(%) |
---|---|---|
AGE (Mean ± SD) | 61.3 ± 4.6 | 63.2 ± 3.96 |
Sex ratio (Male: Female) | 184:26 | 181:21 |
BMI (Kg/m2) (Mean ± SD) | 22.4 ± 2.5 | 28.1 ± 1.7 |
Smokers | 11 (5.2) | 65 (32.1) |
Alcoholic | 17 (8.0)) | 75 (37.1) |
Exercise | 117 (55.7) | 16 (32.3) |
Hypertension | 0 | 66 (29.5) |
MI = myocardial infarction; SD = standard deviation; BMI = body mass index.
The comparison of lipid profiles between controls and patients are showed in Table 2. The TCL, TGL, LDL and VLDL levels were significantly high in patients in comparison with controls (p = 0.0001), where as the HDL levels were significantly high in controls than in patients (p = 0.0001). The association of LPL genotypes with lipid levels between MI patients and controls are summarised in Tables 3 and 4.
Table 2.
Parameters | Controls (Mean ± SD) | Patients (mean ± SD) | t value | p value |
---|---|---|---|---|
TCL (mg/dl) | 168.3 ± 24.0 | 239.8 ± 29.0 | 27.3 | 0.0001 |
TGL (mg/dl) | 137.8 ± 1.5 | 177.3 ± 11.6 | 48.9 | 0.0001 |
LDL (mg/dl) | 98.5 ± 11.9 | 173.6 ± 28.4 | 35.2 | 0.0001 |
HDL (mg/dl) | 42.3 ± 5.3 | 33.8 ± 3.6 | 18.3 | 0.0001 |
VLDL (mg/dl) | 27.3 ± 1.3 | 36.6 ± 1.9 | 58.1 | 0.0001 |
Values represent mean ± standard deviation. MI = myocardial infarction; TCL = total cholesterol; TGL = triglycerides; LDL = low-density lipoprotein; HDL = high-density lipoprotein; VLDL = very-low-density lipoprotein.
Table 3.
Parameters | Genotypes |
||||
---|---|---|---|---|---|
H− H− | H− H+ | H+ H+ | F value | p value | |
TCL (mg/dl) | 215.8 ± 29.1 | 237.1 ± 29.8 | 266.7 ± 28.1 | 45 | 0.001 |
TGL (mg/dl) | 172.4 ± 11.9 | 179.7 ± 11.2 | 180.0 ± 11.7 | 5.6 | 0.004 |
LDL (mg/dl) | 168.2 ± 29.1 | 170.1 ± 27.6 | 182.5 ± 28.5 | 5.3 | 0.005 |
HDL (mg/dl) | 35.6 ± 3.2 | 34.2 ± 3.7 | 31.6 ± 3.9 | 18.2 | 0.001 |
VLDL (mg/dl) | 32.6 ± 2.1 | 39.3 ± 1.8 | 37.9 ± 2.0 | 80 | 0.0001 |
Values represent mean ± standard deviation. MI = myocardial infarction; TCL = total cholesterol; TGL = triglycerides; LDL = low-density lipoprotein; HDL = high-density lipoprotein; VLDL = very-low-density lipoprotein.
Table 4.
Parameters | Genotypes |
||||
---|---|---|---|---|---|
H− H− | H− H+ | H+ H+ | F value | p value | |
TCL (mg/dl) | 164.6 ± 21.6 | 166.1 ± 26.2 | 174.2 ± 24.2 | 3.2 | 0.04 |
TGL (mg/dl) | 134.8 ± 1.4 | 135.6 ± 1.2 | 143.0 ± 1.9 | 25 | 0.01 |
LDL (mg/dl) | 95.8 ± 12.1 | 97.3 ± 11.8 | 102.4 ± 12.0 | 5.8 | 0.03 |
HDL (mg/dl) | 44.2 ± 4.9 | 42.8 ± 5.4 | 40.1 ± 5.6 | 10.9 | 0.03 |
VLDL (mg/dl) | 25.3 ± 1.1 | 28.6 ± 1.5 | 28.0 ± 1.3 | 28 | 0.01 |
Values represent mean ± standard deviation. TCL = total cholesterol; TGL = triglycerides; LDL = low-density lipoprotein; HDL = high-density lipoprotein; VLDL = very-low-density lipoprotein.
The distribution of LPL genotypes and allelic frequencies of the study groups are presented in Table 5. The genotypic association between patients and controls were shown in Table 6. The H+ H+ vs. H− H− was χ2 = 19.4, OR 3.1, CI 95% 1.8–5.2, p < 0.0001; H+ H+ vs. H+ H− was χ2 = 1.4, OR 1.3, CI 95% 0.8–2.0, p > 0.22; H+ H+ vs. H− H− + H+ H− was χ2 = 5.7, OR 0.64, CI 95% 0.4–0.9, p < 0.01. H+ allele was significantly associated with MI: H+ vs. H− was χ2 = 23.8, OR 2.0, CI 95% 1.5–2.6, p < 0.0001.
Table 5.
Study group | LPL genotypes |
Total | Allelic frequencies |
Total | |||
---|---|---|---|---|---|---|---|
H− H− | H− H+ | H+ H+ | H− | H+ | |||
Controls | 72 (34.3) | 68 (32.4) | 70 (33.3) | 210 | 0.51 | 0.49 | 420 |
Patients | 32 (15.9) | 72 (35.6) | 98 (48.5) | 202 | 0.34 | 0.64 | 404 |
LPL: Lipoprotein lipase gene; Percentages provided in parentheses.
Table 6.
Genotypes & alleles (Patients vs. controls) | Chi-square (χ2) | Odds ratio | CI 95% |
||
---|---|---|---|---|---|
L. limit | U. limit | p value | |||
H+ H+ vs. H− H− | 19.4 | 3.1 | 1.8 | 5.2 | 0.0001 |
H+ H+ vs. H+ H− | 1.4 | 1.3 | 0.8 | 2.0 | 0.22 |
H+ H+ vs. H− H− + H+ H− | 5.7 | 0.64 | 0.4 | 0.9 | 0.01 |
H+ vs. H− | 23.8 | 2.0 | 1.5 | 2.6 | 0.0001 |
LPL = Lipoprotein lipase gene; MI = myocardial infarction; CI = confidence interval; L = lower; U = upper.
Multivariate logistic regression analysis was done for adjusting the confounding factors with LPL genotypes. After adjusting the all confounding factors we observed that Homozygous (H+ H+) mutation shows 33 times and Heterozygous (H+ H−) genotype shows 6 times risk of MI as compared with Homozygous (H− H−) genotype.
4. Discussion
LPL plays a central role in the metabolism of lipoproteins and associated with the development of atherosclerosis and coronary heart disease (CHD). LPL gene mutants have been extensively described in human. Number of studies have been focused on the influence of LPL HindIII polymorphism on plasma TG, TC, HDL-C and apolipoproteins levels; however the results are inconsistent.19–21 Although LPL HindIII (rs320) polymorphism is not expected to have any direct functional effect on LPL activity, some of data have demonstrated that H+ allele is associated with higher TG, lower HDL-C level, hyper triglyceridemia, the severity of atherosclerosis and an increased risk of coronary artery disease (CAD).22
We examined the impact of genetic variants of the LPL gene on plasma lipid levels in South Indian population. To our knowledge, this is the first study of its kind in South Indians, a population with very high rates of premature CAD.23
The present study investigated the role of this polymorphism in the development of MI. The frequencies of the H+ H+ genotype and H+ allele were significantly higher in patients compared with controls, indicating the association of LPL gene HindIII polymorphism with the disease. The results of the present study were in accordance with observations of earlier investigators, which support that H+ H+ genotype associated with myocardial infarction.24
Several researchers have identified a significant association between the H+ allele and MI25, while others have shown an association with CAD.26,27 We also got the results with a strong association between the H+ allele and MI. The ECTIM case–control study reported an increased odds ratio (2.1) for MI with HindIII (H+ H+) compared with HindIII (H− H−) genotypes. A higher frequency of the H+ allele is reported in patients with Alzheimer's disease (AD) compared to a control group, suggesting an increased risk of AD in H+ allele carriers indicating that LPL gene HindIII polymorphism showed association with Alzheimer disease.28
Thorn et al, (1990) observed a higher frequency of the H+ allele in patients with atherosclerosis and a recent study showed an association with higher levels of TG, lower levels of HDL, atherosclerosis severity and increased risk of CAD.29 A study of elderly Russian MI patients and elderly controls (>90 years) showed a protective effect of the H–allele.18 A lipid profile with high TG and low HDL is a risk factor for atherosclerosis, which was associated with the H+ allele in several populations and it also proved that polymorphic HindIII site in the LPL gene is functional because it affects the binding of a transcription factor and it also has an impact on LPL expression.29
In the present study, 202 patients and 210 controls were included and our selection criteria were specific for patients with a first MI without previous history of vascular disease. However, patients with cancer, neurological and all kidney diseases were excluded from the study. The classical risk factors and lipid profiles were significantly high in patients in comparison with controls, which is consistent with previous studies.19 We have observed that the LPL gene HindIII H+ H+ genotype frequency was significantly associated with MI patients in South Indian population. Similar results on MI in Brazil and Russian population have been observed.24 Infact, studies on the LPL gene HindIII polymorphism are very limited in India. Moreover, there are no reports on the LPL gene HindIII polymorphism in MI from an Indian population.
To the best of our knowledge, this is the first study to investigate the association of the LPL gene HindIII polymorphism in MI in a South Indian population. However, it warrants further study in a larger cohort to confirm the association of this gene polymorphism.
5. Conclusion
Our data strongly suggest that the LPL gene HindIII H+ H+ genotype is a independent risk factor for first MI.
Conflicts of interest
All authors have none to declare.
Acknowledgments
We thank the patients and their families for their valuable contribution. We also thank N. Bala Krishna for performing the statistical analysis and Sreenivas Adurthi for their help in editing the paper.
References
- 1.Braunwald E., editor. Heart Disease: A Textbook of Cardiovascular Medicine. W.B. Saunders; Philadelphia: 1997. [Google Scholar]
- 2.Eckel R.H. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med. 1989;320:1060–1068. doi: 10.1056/NEJM198904203201607. [DOI] [PubMed] [Google Scholar]
- 3.Mulder M., Lombardi P., Jansen H. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparin sulfate proteoglycans via lipoprotein lipase. J Biol Chem. 1993;268:9369–9937. [PubMed] [Google Scholar]
- 4.Oka K., Tkalcevic G.T., Nakano T. Structure and polymorphic map of human lipoprotein lipase gene. Biochim Biophys Acta. 1990;1049:21–26. doi: 10.1016/0167-4781(90)90079-h. [DOI] [PubMed] [Google Scholar]
- 5.Deeb S.S., Peng R.L. Structure of the human lipoprotein lipase gene. Biochemistry. 1989;28:4131–4135. doi: 10.1021/bi00436a001. [DOI] [PubMed] [Google Scholar]
- 6.Gotoda T., Yamada N., Murase T. Detection of three separate DNA polymorphisms in the human lipoprotein lipase gene by gene amplification and restriction endonuclease digestion. J Lipid Res. 1992;33:1067–1072. [PubMed] [Google Scholar]
- 7.Heizmann C., Kirchgessner T., Kwiterovich P.O. DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels. Hum Genet. 1991;86:578–584. doi: 10.1007/BF00201544. [DOI] [PubMed] [Google Scholar]
- 8.Gerdes C., Gerdes L.U., Hansen P.S. Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men. Circulation. 1995;92:1765–1769. doi: 10.1161/01.cir.92.7.1765. [DOI] [PubMed] [Google Scholar]
- 9.Stocks J., Thorn J.A., Galton D.J. Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion. J Lipid Res. 1992;33:853–857. [PubMed] [Google Scholar]
- 10.Peacock R.E., Hamsten A., Nilsson-Ehle P. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis. 1992;97:171–185. doi: 10.1016/0021-9150(92)90130-9. [DOI] [PubMed] [Google Scholar]
- 11.Georges J.L., Regis-Bailly A., Salah D. Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. Genet Epidemiol. 1996;13:179–192. doi: 10.1002/(SICI)1098-2272(1996)13:2<179::AID-GEPI4>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
- 12.Mattu R.K., Needham E.W., Morgan R. DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. Arterioscler Thromb Vasc Biol. 1994;14:1090–1097. doi: 10.1161/01.atv.14.7.1090. [DOI] [PubMed] [Google Scholar]
- 13.Mitchell R.J., Earl L., Bray P. DNA polymorphisms at the lipoprotein lipase gene and their association with quantitative variation in plasma high-density lipoproteins and triacylglycerides. Hum Biol. 1994;66:383–397. [PubMed] [Google Scholar]
- 14.Chamberlain J.C., Thorn J.A., Oka K. DNA polymorphisms at the lipoprotein lipase gene: associations in normal and hypertriglyceridemia subjects. Atherosclerosis. 1989;79:85–91. doi: 10.1016/0021-9150(89)90037-3. [DOI] [PubMed] [Google Scholar]
- 15.Thorn J.A., Chamberlain J.C., Alcolado J.C. Lipoprotein and hepatic lipase gene variants in coronary atherosclerosis. Atherosclerosis. 1990;85:55–60. doi: 10.1016/0021-9150(90)90182-i. [DOI] [PubMed] [Google Scholar]
- 16.Razzaghi H., Aston C.E., Hamman R.F. Genetic screening of the lipoprotein lipase gene for mutations associated with high triglyceride/low HDL-cholesterol levels. Hum Genet. 2000;107:257–267. doi: 10.1007/s004390000367. [DOI] [PubMed] [Google Scholar]
- 17.Ahn Y.I., Kamboh M.I., Hamman R.F. Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease. J Lipid Res. 1993;34:421–428. [PubMed] [Google Scholar]
- 18.Malygina N.A., Melent'ev A.S., Kostomarova I.V. Connection of HindIII-polymorphism in the lipoprotein lipase gene with myocardial infarct and life span in elderly ischemic heart disease patients. Mol Biol (Mosk) 2001;35:787–791. [PubMed] [Google Scholar]
- 19.Ma Y.Q., Thomas G.N., Ng M.C. The lipoprotein Lipase gene HindIII polymorphism is associated with lipid levels in early-onset type 2 diabetic patients. Metabolism. 2003;52:338–343. doi: 10.1053/meta.2003.50053. [DOI] [PubMed] [Google Scholar]
- 20.Merkel M., Eckel R.H., Goldberg I.J. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res. 2002;43:1997–2006. doi: 10.1194/jlr.r200015-jlr200. [DOI] [PubMed] [Google Scholar]
- 21.Murthy V., Julien P., Gagne C. Molecular path biology of the human lipoprotein lipase gene. Pharmacol Ther. 1996;70:101–135. doi: 10.1016/0163-7258(96)00005-8. [DOI] [PubMed] [Google Scholar]
- 22.Ye P., Pei L., Wang S. Polymorphisms of the human lipoprotein lipase gene: possible association with lipid levels in patients with coronary heart disease in Beijingarea. Chin Med Sci J. 1996;11:157–161. [PubMed] [Google Scholar]
- 23.Mohan V., Deepa R. Risk factors for coronary artery disease in Indians. J Assoc Physicians India. 2004;52:95–97. [PubMed] [Google Scholar]
- 24.Gigek Cde O., Chen E.S., Cendoroglo M.S. Association of lipase lipoprotein polymorphism with myocardial infarction and lipid levels. Clin Chem Lab Med. 2007;45:599–604. doi: 10.1515/CCLM.2007.115. [DOI] [PubMed] [Google Scholar]
- 25.Jemaa R., Fumeron F., Poirier O. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Temoin sur l’Infarctus du Myocarde. J Lipid Res. 1995;6:2141–2146. [PubMed] [Google Scholar]
- 26.Anderson J.L., King G.J., Bair T.L. Association of lipoprotein lipase gene polymorphisms with coronary artery disease. J Am Coll Cardiol. 1999;33:1013–1020. doi: 10.1016/s0735-1097(98)00677-9. [DOI] [PubMed] [Google Scholar]
- 27.Long S., Tian Y., Zhang R. Relationship between plasma HDL subclasses distribution and lipoprotein lipase gene HindIII polymorphism in hyperlipidemia. Clin Chim Acta. 2006;366:316–321. doi: 10.1016/j.cca.2005.11.010. [DOI] [PubMed] [Google Scholar]
- 28.Scacchi R., Gambina G., Broggio E. The H+ allele of the lipoprotein lipase (LPL) HindIII intronic polymorphism and the risk for sporadic late-onset Alzheimer's disease. Neurosci Lett. 2004;367:177–180. doi: 10.1016/j.neulet.2004.05.111. [DOI] [PubMed] [Google Scholar]
- 29.Chen Q., Razzaghi 1 Hamid, Demirci F.Y. Functional Significance of lipoprotein lipase HindIII polymorphism associated with the risk of coronary artery disease. Atherosclerosis. 2008 Sep;200:102–108. doi: 10.1016/j.atherosclerosis.2007.12.011. Epub 2008 Feb 1. [DOI] [PMC free article] [PubMed] [Google Scholar]